Abstract:Extranodal NK/T cell lymphoma, nasal type (ENKTL) is an aggressive malignancy with a dismal prognosis. Although L-asparaginase-based chemotherapy has resulted in improved response rates, relapse occurs in up to 50% of patients with disseminated disease. There is hence an urgent need for effective targeted therapy, especially for patients with relapsed or refractory disease. Novel insights gleaned from high-throughput molecular and genomic profiling studies in recent years have contributed significantly to the understanding of the molecular biology of ENKTL, which exemplifies many of the hallmarks of cancer. Deregulated pro-proliferative signaling pathways, such as the Janus-associated kinase/signal transducer and activator of transcription (JAK/STAT), platelet-derived growth factor (PDGF), Aurora kinase, MYC, and NF-κB, have been identified as potential therapeutic targets. The discovery of the non-canonical function of EZH2 as a pro-proliferative transcriptional co-activator has shed further light on the pathogenesis of ENKTL. Loss of key tumor suppressor genes located on chromosome 6q21 also plays an important role. The best-studied examples include PR domain zinc finger protein 1(PRDM1), protein tyrosine phosphatase kappa (PTPRK), and FOXO3. Promoter hypermethylation has been shown to result in the downregulation of other tumor suppressor genes in ENKTL, which may be potentially targeted through hypomethylating agents. Deregulation of apoptosis through p53 mutations and upregulation of the anti-apoptotic protein, survivin, may provide a further growth advantage to this tumor. A deranged DNA damage response as a result of the aberration of ataxia telangiectasia-related (ATR) kinases can lead to significant genomic instability and may contribute to chemoresistance of ENKTL. Recently, immune evasion has emerged as a critical pathway for survival in ENKTL and may be a consequence of HLA dysregulation or STAT3-driven upregulation of programmed cell death ligand 1 (PD-L1). Immunotherapy via inhibition of programmed cell death 1 (PD-1)/PD-L1 checkpoint signaling holds great promise as a novel therapeutic option. In this review, we present an overview of the key molecular and pathogenic pathways in ENKTL, organized using the framework of the "hallmarks of cancer" as described by Hanahan and Weinberg, with a focus on those with the greatest translational potential.

Autocrine PDGF/PDGFR Loop in the Proliferation of NK/T-cell Lymphoma Cells

Pathological features and prognosis of natural killer cell lymphoma and leukemia

NK-cell dysfunction in human renal carcinoma reveals diacylglycerol kinase as key regulator and target for therapeutic intervention

Phosphodiesterase 4A Confers Resistance to PGE2-mediated Suppression in CD25+ /CD54+ NK Cells.

Natural Killer Cells Control Tumor Growth by Sensing a Growth Factor

Gelsolin Regulates Proliferation, Apoptosis and Invasion in Natural Killer/t-Cell Lymphoma Cells

[Effect of PD-L1 Expression on Activity of NK Killing AML Cell Lines and Its Mechanisms].

Overexpression of PTPN21 Promotes Proliferation of EGF-stimulated Acute Lymphoblastic Leukemia Cells Via the MAPK Signaling Pathways

PRDM1 Expression and Its Relationship with PI3K/AKT Pathway Activation in Extranodal NK/T Cell Lymphoma-Nasal Type

Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK/T-cell lymphoma, nasal type

The Acetyltransferase KAT5 Inhibitor NU 9056 Promotes Apoptosis and Inhibits JAK2/STAT3 Pathway in Extranodal NK/T Cell Lymphoma

[Effects of AKT Protein Kinase Activation on Biologic Behavior of Diffuse Large B Cell Lymphoma Cells].

Hypoxia‐inducible Factor‐1α and Nuclear Factor‐κb Play Important Roles in Regulating Programmed Cell Death Ligand 1 Expression by Epidermal Growth Factor Receptor Mutants in Non‐small‐cell Lung Cancer Cells

Differential Roles of Constitutively Activated Erk1/2 and Nf-Kappa B in Cytotoxicity and Proliferation by Human Nk Cell Lines

GDNF secreted by nerves enhances PD-L1 expression via JAK2-STAT1 signaling activation in HNSCC.

Molecular pathogenic pathways in extranodal NK/T cell lymphoma

NEK2 Promotes Cell Proliferation and Glycolysis by Regulating PKM2 Abundance via Phosphorylation in Diffuse Large B-Cell Lymphoma

Programmed Cell Death Protein 1/Programmed Cell Death Ligand-1 Axis activates Intracellular ERK Signaling in Tumor Cells to Mediate Poor Prognosis in T-cell Lymphoma

[Effect of Nucleolin on Lymphoma Proliferation by Regulating Thymidine Kinase 1]

Effects of Endogenous Epidermal Growth Factor Receptor Signaling on DNA Synthesis and ERK Activation in a Cytokine-Dependent Hematopoietic Cell Line

6P Mechanisms of Regulating PD-L1 Expression in Non-Small Cell Lung Cancer During EMT Process